WASHINGTON - US biotech firm Moderna said Wednesday that doses of its new COVID-19 vaccine candidate aimed at the South African coronavirus variant had been shipped to the US National Institutes of Health for testing.
That means people who were infected with the classic strain are more susceptible to reinfection, and research has also shown the variant has partly reduced the protection of the current generation of vaccines. Another idea is that people could receive a third dose of the classic vaccine to raise their overall immunity.
Ey, we have a chance in 2022!
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: